{"id":9504,"date":"2020-08-13T11:19:26","date_gmt":"2020-08-12T22:19:26","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=9504"},"modified":"2020-08-13T11:23:54","modified_gmt":"2020-08-12T22:23:54","slug":"ball-score-predicts-benefit-from-ibrutinib-in-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=9504","title":{"rendered":"Ball Score Predicts Benefit From Ibrutinib in CLL"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Ball Score Predicts Benefit From Ibrutinib in CLL<\/h1>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by MedScape<\/a><\/p>\n

The BALL score was able to identify a subset of patients with\u00a0chronic lymphocytic leukemia<\/a>\u00a0(CLL) who particularly benefit from single-agent\u00a0ibrutinib<\/a>\u00a0therapy, according to the results of a study of 111 patients followed from two different institutions.<\/p>\n

The BALL model consists of four factors: serum beta\u2082-microglobulin at 5 mg\/dL or greater, hemoglobin < 110 g\/L for women or < 120 g\/L for men, lactate dehydrogenase [LDH] > upper limit of normal [UNL], and time elapsed from last therapy less than 24 months. Each parameter was alloted 1 point, leading to a stratification of patients into three different prognostic groups: low risk (score 0-1), intermediate risk (2-3), and high risk (score 4), according to\u00a0a report<\/a>\u00a0published online in Leukemia Research.<\/p>\n

According to\u00a0Stefano Molica, MD<\/a>, of the Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy, and his colleagues, the majority of patients (82%) were clinical Rai stage II-IV. The median patient age was 63 years and nearly 68% were men.<\/p>\n

The researchers assessed four models for predicting overall survival. The modified version of CLL-International Prognostic Index (CLL-IPI) failed to provide prognostic information in relapsed\/refractory (R\/R) CLL (P<\/em>\u00a0= .77) as did the Ahn et al. model (P<\/em>\u00a0= .95) and a simplified BALL model (P<\/em>\u00a0= .09). In contrast, the full BALL score captured two groups of patients with significant differences in survival (hazard ratio, 0.240; 95 % confidence interval, 0.10-0.54;\u00a0P<\/em>\u00a0= .0005); however, because of the low number of patients in the high-risk category, these cases were combined with the intermediate-risk group.<\/p>\n

<\/div>\n

The BALL score identified a subset of patients, accounting for about 50% of the whole population, who particularly benefit from single-agent ibrutinib, according to Dr. Molica and his colleagues. These patients had a survival rate of 85% at 3 years.<\/p>\n

“In contrast, the outcome of subjects with intermediate-high risk is disappointing. These patients should be considered for a combination of targeted drugs or cellular-based therapies,” the researchers concluded.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

The BALL score was able to identify a subset of patients with chronic lymphocytic leukemia (CLL) who particularly benefit from single-agent ibrutinib therapy,<\/p>\n","protected":false},"author":1,"featured_media":9507,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17,23],"tags":[],"class_list":["post-9504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/08\/CLL-DARK-PURPLE.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/9504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9504"}],"version-history":[{"count":3,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/9504\/revisions"}],"predecessor-version":[{"id":9512,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/9504\/revisions\/9512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/9507"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}